In a move that could reshape the future of personalized medicine, a new scientific study conducted by the University of California, Los Angeles, has revealed the importance of ethnic diversity in genetic research, illustrating how this diversity can uncover unprecedented links between genes and disease risk, as well as how patients respond to treatment.
The study, led by researchers from the University of California and published in the journal Cell on March 27, 2026, relied on the analysis of data from nearly 94,000 participants within a biobank known as ATLAS, which is one of the most diverse databases in the world regarding ethnic backgrounds.
Event Details
Previous genetic studies have heavily relied on samples from European ancestry, limiting the generalizability of their findings to the rest of the global population. However, this study presents a different model, including participants from diverse backgrounds that reflect the vast diversity of Los Angeles.
Daniel Gishwind, the lead researcher in the study from the Department of Human Genetics at the University of California, stated that these are not limited laboratory results but reflect real data from diverse patients, making them applicable to groups that have long been overlooked in medicine.
Among the most notable findings of the study is that genes may significantly influence how patients respond to weight-loss medications from the GLP-1 class, which mimic a natural hormone in the body that helps regulate appetite and blood sugar. One of the most well-known treatments in this category is Semaglutide, available under brand names such as Ozempic and Wegovy.
Background & Context
The results indicated that the effectiveness of these medications varies among individuals based on their genetic backgrounds and is particularly associated with the genetic risk level for developing type 2 diabetes. A new genetic link was also identified between patient responses to treatment and a gene known as PTPRU, a discovery that may pave the way for the development of more precise treatments in the future.
The study's findings were not limited to medications alone but extended to a deeper understanding of disease risks. Researchers were able to identify new genetic links that were previously unknown, especially when analyzing rare genetic variants.
For instance, the gene ANKZF1 was linked to peripheral vascular disease in individuals of African descent. Additionally, a relationship was found between the gene EPG5 and blood lipid levels in individuals of Ashkenazi Jewish descent.
Impact & Consequences
The study also demonstrated that certain population groups, such as those of Mexican or South American descent, may be more susceptible to specific side effects of hormonal treatments.
One of the important tools discussed in the study is known as Polygenic Risk Scores, which are indicators calculated based on hundreds or thousands of genetic variants to estimate the likelihood of developing diseases such as diabetes, heart disease, and cancer.
The results showed that this tool could be close to clinical use, as thousands of individuals at high risk for common diseases, such as type 1 diabetes, were identified.
However, researchers emphasize the need for further studies before these findings can be widely adopted in healthcare systems.
Regional Significance
In a move that reshapes the medical research landscape, the ATLAS biobank stands out as an exceptional model that integrates genetic data with electronic health records, providing a unique platform to study the interaction between genes and health in a real-world environment, away from the confines of traditional laboratories.
Researcher Roni Haas from the Department of Human Genetics at the University of California, the principal author of the study, asserts that many previous studies lacked sufficient population diversity, while ATLAS reflects the composition of a real, multi-ethnic community, lending exceptional strength and realism to scientific results.
These findings indicate a significant shift in how diseases are understood and treated. Instead of relying on a one-size-fits-all approach, medicine is moving toward a stage where treatment can be tailored according to each individual's genetic makeup.
As this research continues to expand, it seems that the future of medicine will not only rely on diagnosing diseases but also on understanding the genetic map of each patient, which could change the game in healthcare worldwide.